Gambichler T, Breininger A, Rotterdam S, Altmeyer P, Stücker M, Kreuter A
Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
J Eur Acad Dermatol Venereol. 2009 Oct;23(10):1184-8. doi: 10.1111/j.1468-3083.2009.03285.x. Epub 2009 May 6.
Minichromosome maintenance (MCM) nuclear proteins have barely been employed in the diagnosis of skin malignancies. We aimed to assess whether MCM immunohistochemistry can be utilized to examine tumour proliferation in Merkel cell carcinoma (MCC).
In this pilot study, we studied skin specimens of eight patients with MCC. As a control, eight patients with cutaneous malignant melanoma (MM) were included. Immunohistochemistry was performed for MCM4, MCM6, MCM7, Ki-67, p53, and p21.
Protein expression of MCM4 (66.0 +/- 26.5% vs. 33.9 +/- 22.4%; P = 0.017), MCM6 (70.9 +/- 11.9 vs. 31.7 +/- 22.7; P = 0.0031), and MCM7 (76.5 +/- 16.4% vs. 34.9 +/- 25.5%; P = 0.0013) was significantly increased in tumour cells of MCC when compared to tumour cells of MM. Ki-67 immunoreactivity was also significantly higher in MCC than in MM (28.7 +/- 7.9 vs. 11.0 +/- 9.2; P = 0.0012). Immunolabelling of p53 (68.6 +/- 26.2 vs. 58.4 +/- 28.8; P = 0.46) and p21 (40.1 +/- 38.8 vs. 25.8 +/- 16.1; P = 0.35) was relatively high but not significantly increased in MCC when compared to MM.
Our preliminary data indicate that MCM immunohistochemistry may be a useful tool for the determination of tumour cell proliferation in MCC.
微小染色体维持(MCM)核蛋白在皮肤恶性肿瘤的诊断中几乎未被应用。我们旨在评估MCM免疫组化是否可用于检测默克尔细胞癌(MCC)中的肿瘤增殖情况。
在这项前瞻性研究中,我们研究了8例MCC患者的皮肤标本。作为对照,纳入了8例皮肤恶性黑色素瘤(MM)患者。对MCM4、MCM6、MCM7、Ki-67、p53和p21进行免疫组化检测。
与MM肿瘤细胞相比,MCC肿瘤细胞中MCM4(66.0±26.5%对33.9±22.4%;P = 0.017)、MCM6(70.9±11.9对31.7±22.7;P = 0.0031)和MCM7(76.5±16.4%对34.9±25.5%;P = 0.0013)的蛋白表达显著增加。MCC中Ki-67免疫反应性也显著高于MM(28.7±7.9对11.0±9.2;P = 0.0012)。与MM相比,MCC中p53(68.6±26.2对58.4±28.8;P = 0.46)和p21(40.1±38.8对25.8±16.1;P = 0.35)的免疫标记相对较高,但无显著增加。
我们的初步数据表明,MCM免疫组化可能是确定MCC中肿瘤细胞增殖的有用工具。